A Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults With Poor Risk CD30+ Hodgkin Lymphoma (HL)
Phase of Trial: Phase I/II
Latest Information Update: 15 Mar 2019
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Busulfan; Cyclophosphamide; Fludarabine; Gemcitabine; Melphalan
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 11 Mar 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 11 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 28 Mar 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.